Novo Nordisk's Wegovy pill maintains strong lead over Eli Lilly rival despite weekly dip, Citi says

Novo Nordisk's (NYSE:NVO) oral version of its blockbuster weight-loss drug Wegovy continues to outpace its main competitor despite a slight weekly decline in prescriptions, according to Citi's latest tracking data. The bank's weekly prescription tracker, based on IQVIA data, showed Wegovy pill reaching approximately 137,000 total prescriptions in its 18th week on the US market, a 4% decline week on week.